December 4. 2024: 

A Big Ten Cancer Research Consortium trial titled, “Alpelisib (BYL719) with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (BTCRC-BRE19-409)” has been accepted for a poster presentation at the 2024 San Antonio Breast Cancer Symposium on December 11, 2024 from 5:30 pm – 7:00 pm.

Congratulations to all co-authors and study teams involved in the study!

Read More

December 2, 2024: 

A Big Ten Cancer Research Consortium (Big Ten CRC) study, BTCRC-LUN16-081, led by Greg Durm, MD, of IU Simon Comprehensive Cancer Center, was published in the Journal of Thoracic Oncology in October 2024. The article is titled, “Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.”

Congratulations to all co-authors and study teams whose hard work led to this publication.

Read More